Key Highlights

  • A Delaware federal Jury found that several of Cytek Biosciences' cell-analysis products infringe a Patent held by rival Beckman Coulter, ordering the company to pay $56 million in damages.
  • Second-quarter 2026 Revenue reached $48.1 million, up 6% year over year, with GAAP Gross Profit rising 19% to $28.3 million.
  • Net loss widened to $12.2 million from $5.6 million a year earlier, driven in part by litigation-related costs the company had already flagged ahead of the verdict.
  • Management raised full-year 2026 revenue guidance modestly to a range of $207 million to $212 million, with the installed instrument base growing to 3,933 units by quarter-end.

Cytek Biosciences, Inc. (NASDAQ:CTKB) is weighing its next legal steps after a Delaware jury ruled that several of its spectral flow cytometry products infringe a patent held by Beckman Coulter, a Danaher subsidiary, and ordered the company to pay $56 million in damages.

The verdict, made public on August 21, 2026, arrived just weeks after Cytek reported second-quarter results showing continued, if modest, revenue growth alongside a widening net loss. The company had already pointed to elevated litigation-related costs in that Earnings release, suggesting management anticipated meaningful legal expense even before the jury's decision became public.

Cytek builds spectral flow cytometry instruments used by researchers and clinical labs to analyze cells at high resolution, competing directly against larger, better-capitalized players including Beckman Coulter, BD Biosciences, and Thermo Fisher.

The Patent Verdict

The Delaware jury ruled on the core infringement question against Cytek, though coverage of the case indicates the company prevailed on some of the other underlying claims, making it a mixed but costly outcome. The dispute centers on cell-analysis technology used across Cytek's product lines.

A mixed verdict of this kind often invites appeals from the losing side on the adverse claims, a process that can extend for years and consume both legal budget and management attention. The ultimate cash outlay could still shift through post-trial motions or a negotiated settlement.

Second-Quarter Results and Guidance

Cytek's core Business continued to grow modestly in the second quarter of 2026. Revenue came in at $48.1 million, up 6% year over year, following $44.1 million in the first quarter, also up 6%. GAAP gross profit rose 19% to $28.3 million, pointing to some Margin improvement in the underlying business.

Net loss widened to $12.2 million for the quarter, compared with $5.6 million a year earlier, a result the company attributed to higher operating expenses, including litigation costs and increased personnel spending. Management raised full-year 2026 revenue guidance modestly to a range of $207 million to $212 million, and the installed base of instruments grew to 3,933 units by the end of the quarter, a reasonable proxy for continued customer adoption.

Product and Business Developments

Alongside its financial results, Cytek has continued to invest in its product lineup in 2026, launching the Borealis 7-laser flow cytometer and new Aurora Evo configurations, and opening an innovation center in Bellevue, Washington to support research and customer engagement.

These moves reflect a company still expanding its commercial footprint even as it absorbs the cost and uncertainty of the patent litigation, underscoring that the legal outcome and the underlying commercial trajectory are, for now, two largely separate storylines.

The Investment Case

Cytek occupies a niche but growing corner of the life-sciences tools market, spectral flow cytometry, which allows researchers to distinguish far more cell markers simultaneously than older instrument generations. The bull case rests on continued adoption of the company's Aurora and Northern Lights platforms across academic, biopharma, and increasingly clinical settings, alongside steady revenue growth and gradually improving gross margins.

The bear case centers on the company's persistent GAAP losses, intensifying competition from larger rivals, and now a meaningful legal Liability that could pressure cash reserves or force costly product design-arounds if an injunction is eventually pursued. Wall Street coverage remains thin: three analysts reportedly track the stock, with one Buy and two Hold ratings.

What Comes Next

Investors should watch for whether Cytek pursues an appeal of the Beckman Coulter verdict, and for any court rulings on post-trial motions or a potential injunction request, since either could materially change the practical impact of the case. The company's next quarterly report, likely in early November for the third quarter, will show whether litigation costs continue to weigh on margins.

Any disclosure on cash position and whether the $56 million liability, or a portion of it, gets reserved on the Balance Sheet or paid out will matter for near-term liquidity. Continued adoption metrics for the Borealis and Aurora Evo platforms will also help clarify whether the underlying commercial story remains on track.

Steady Growth Meets a Costly Legal Setback

Cytek Biosciences' patent verdict is a specific, verifiable setback layered on top of a business that continues to grow revenue, even as net losses widen. The combination gives both bulls and bears fresh evidence: steady top-line growth and product innovation on one side, legal liability and profitability concerns on the other.

Investors evaluating CTKB should weigh the litigation's ultimate financial and competitive impact against the company's underlying commercial trajectory in the expanding spectral flow cytometry market, rather than treating the verdict as a simple binary outcome.